More than two billion people worldwide live with metabolic and cardiovascular diseases, including nearly one billion living with obesity. As global populations age, the burden of these diseases is only expected to grow. Conventional drug development typically treats single diseases late in their progression, often after they have already emerged, consequently failing to address the integrated physiological decline due to aging.
BioAge Labs is pursuing a different approach: proactive, multi-disease therapeutic approaches that target the fundamental biological drivers of human aging to prevent early chronic morbidity. Led by CEO and co-founder Kristen Fortney, Ph.D., the clinical-stage biopharmaceutical is building a drug pipeline and a patent portfolio around this strategy.
NLRP3 and BGE-102: Clinical development and pipeline
A key factor in the “aging” problem is the biology of chronic inflammation, or “inflammaging.” BioAge Labs is among the companies advancing drugs that target the chronic activation of the NLRP3 inflammasome, a process implicated in metabolic, cardiovascular, retinal, and neurodegenerative disorders.
Reflecting this, biotech and pharma leaders are investing heavily in the space, developing therapeutics intended to complement popular GLP-1/GIP agonists. This rationale is supported by Phase 2 data from Ventyx Biosciences, a separate NLRP3-focused drug developer, unaffiliated with BioAge, whose combination trials of its inhibitor VTX3232 with semaglutide were designed to test whether such pairings can enable weight loss while lowering systemic cardiac risk, a commercial opportunity highlighted by Eli Lilly’s recent $1.2 billion acquisition of NLRP3-focused Ventyx.
The BioAge Labs’ lead clinical candidate, BGE-102, is a structurally novel, orally available, and brain-penetrant small-molecule NLRP3 inhibitor. Phase 1 clinical data reported in April 2026 showed that a once-daily oral dose of BGE-102 achieved rapid, profound median reductions of 85% to 86% in high-sensitivity C-reactive protein (hsCRP), a critical biomarker of systemic inflammation and cardiovascular risk. Furthermore, up to 93% of obese participants reached normalized hsCRP levels (<2 mg/L), while BGE-102’s cerebrospinal fluid concentrations exceeded the IC90 at doses of 60 mg and above which is a key differentiator from other NLRP3 inhibitors in development.
Longevity: BioAge’s core patents target inflammaging and muscle loss
BioAge Labs IP protection bridges the gap between machine-learning longevity diagnostics, selective inflammasome inhibitors, and exercise-mimetic muscle regeneration. By examining these cornerstone patents, we can decode the specific scientific solutions driving BioAge’s clinical candidates.
Decoding biological age: Data-driven survival prediction using metabolomic signatures
Human aging is complex, driven by genetic and environmental factors integrated within the metabolome.
Traditional clinical diagnostics rely on late-stage indicators, failing to capture real-time biological aging or measure short-term therapeutic efficacy. Researchers need an objective proxy for mortality to study aging over manageable timeframes.
U.S. Patent No. 11,881,311 describes a computer-implemented system and method for generating a survival metric for a subject. This patented “aging clock” technology evaluates biological frailty, identifies high-risk populations, and optimizes therapies. Crucially, it enables biopharma companies to study longevity drugs in short-term trials rather than waiting decades for mortality endpoints. According to the patent, this metric can generate biologically risk-adjusted life insurance policies.
The process operates by obtaining a metabolomic dataset from a biological sample representing metabolite values for each of at least n-survival biomarkers (such as polar and lipid metabolites, including glucuronate, citrate, adipic acid, isocitrate, and lactate, or specific lipid subclasses). The system accesses a default state representing normalized biological distributions in a population, and uses a survival predictor model to mathematically combine these metabolite values to generate a survival metric. A generated survival metric value greater than 1 indicates a decreased relative survival risk.
The patent, titled “Survival prediction using metabolomic profiles”, was filed on February 7, 2018, and granted on January 23, 2024 to BioAge Labs, Inc. The patent lists Kristen Fortney, Yonatan Donner, Eric Morgen, Jonah Sinick, and Andrew Ho as inventors. Legal representation is provided by Fenwick & West LLP.
Heterocyclic NLRP3 blockade: Combating inflammaging at the upstream molecular node
Chronic NLRP3 inflammasome activation drives various age-related systemic and neuroinflammatory disorders, including cardiovascular disease, diabetic macular edema (DME), and hearing loss. Current anti-inflammatory treatments lack selectivity, causing systemic side effects, and generally cannot cross the blood-brain barrier to treat central nervous system (CNS) conditions.
U.S. Patent No. 11,708,334 describes a class of compounds designed to solve the problem of chronic, age-related inflammation, commonly referred to as “inflammaging”. This patent covers the core chemical composition of BioAge’s lead clinical asset, BGE-102, whose unique heterocyclic structure enables high oral bioavailability and brain penetrance. This foundation supports BGE-102’s development as a potential best-in-class, once-daily oral therapy targeting cardiovascular risks, retinal disorders, and CNS diseases.
The patent introduces a class of newly designed chemical compounds that act as highly selective “off-switches” for NLRP3 inflammasome cellular alarm systems. These compounds are designed to bind directly to a distinct region on the NLRP3 protein. When this system is constantly turned on, it mistakenly floods the body with harmful inflammatory chemicals. By binding to this specific spot, the molecules block the alarm from activating, effectively stopping the downstream pro-inflammatory pathway and preventing chronic inflammation from damaging cells and tissues.
The patent, titled “Inhibitors of NLRP3 inflammasome”, was filed on September 9, 2022, and granted on July 25, 2023 to BioAge Labs, Inc.. The patent lists George Hartman, Paul Humphries, and Kevin Wilhelmsen as inventors and. Brian Trinque and Nicole Sassu from Lathrop GPM LLP represented BioAge in the prosecution.
Preventing muscle loss and reversing sarcopenia
Aging causes a decline in muscle mass, strength, and function, leading to sarcopenia and frailty, which is accelerated by bed rest during hospitalization. Currently, no approved drugs prevent acute muscle wasting or maintain protein synthesis in these patients.
BioAge’s recent patent application validates BGE-105’s efficacy: in a Phase 1b bed rest trial of older volunteers, once-daily doses reduced vastus lateralis muscle thickness loss by 75% and cross-sectional area loss by >50% compared to placebo, while improving recovery. This supports BioAge’s Phase 2 strategy to prevent ICU mechanical ventilation-induced diaphragmatic atrophy and critical illness myopathy.
U.S. Pat. App. No. 2024/0122926 describes a method for treating or preventing a muscle condition (such as sarcopenia, disuse atrophy, diaphragm atrophy, or critical illness myopathy) or maintaining/increasing muscle mass and strength in a subject (specifically an elderly human at least 60 years old) by administering an effective dose of a highly selective, small-molecule apelin receptor (APJ/APLNR) agonist.
The patent application focuses specifically on the compound BGE-105 (also known as AMG-986). Apelin is an endogenous “exercise mimetic” peptide secreted in response to physical activity. By selectively activating the APJ receptor, BGE-105 mimics the biological benefits of exercise, upregulating mitochondrial biogenesis regulators (like PGC-1α), protecting respiratory complexes, and maintaining the synthesis of key structural myofibrillar proteins like troponin and myosin.
The patent application, titled “Apelin receptor modulators for treating muscle conditions”, was filed on September 27, 2023, and published on April 18, 2024 to BioAge Labs, Inc.. The patent lists Kristen Fortney, Eric Morgen, Robert Hughes, and Fred Aswad, Peng Khun Leong, Sashanaz H. Igdari, Paul David Rubin, and Rusty Lee Montgomery as inventors.
BioAge Labs: Patenting Activity
BioAge Labs’ global patent filings reflect its growth from an early-stage discovery platform to a clinical-stage developer.
After an initial series of patent filings between 2017 and 2020, the company experienced a significant surge in 2021. That same year, BioAge entered into a licensing agreement with Amgen, to develop and commercialize BGE-105, Amgen’s clinical-stage APJ agonist. In 2024, BioAge completed its IPO,
BioAge Labs: Top Law Firms
BioAge works with several law firms for the prosecution of its patent applications, with Lathrop GPM and Fenwick & West representing the largest shares.
Cross-border regulatory protection and regional filings are further managed by patent firms including Kilburn & Strode LLP in Europe, Kim, Choi & Lim (Law Firm KCL) in South Korea, and Deacons in Hong Kong.
BioAge Labs: Top Technology Areas
BioAge’s patent portfolio is heavily oriented toward active therapeutic agents and medical preparations. The leading technology classification is A61P (specific therapeutic activity of chemical compounds or medicinal preparations), representing 29.7% of the IP filings, followed closely by A61K (preparations for medical, dental, or toilet purposes) at 28.6%.
The company’s proprietary computational discovery platform is supported by classifications in G16B (bioinformatics) at 2.7%, G16H (healthcare informatics), G06N (computing arrangements based on specific computational models) G06F (electric digital data processing) with all at 1.1% each.